Project: Targeted delivery of PEGylated adeno-associated viral vectors
2010-01-01 – 2015-12-31
- Abstract
The recent discovery of genes that play a role in the development of life-threatening diseases, including cancer and certain viral infections has significantly stimulated the research into new treatment options based on genes and recently also "small interfering" RNAs (siRNAs). Genes and siRNAs have a great therapeutic potential, but when after administration to patients they are unable to reach the desired cells and cannot penetrate into these cells the likelihood of a therapeutic effect is nil. The development of genes and siRNA as a new class of drugs depends therefore on the availability of safe and effective delivery systems for therapeutic nucleic acids. The in vitro evaluation and development of new non-viral gene delivery systems and siRNA's since 1997 is a major theme within the research of the Ghent promoters. This in vitro study is in a stage where information about the in vivo behavior of the nucleic acid delivery systems containing therapeutic genes or siRNA needs to be evaluated. This brings us to the goal of this research project being the in vivo evaluation of promising therapeutic genes developed within the research of the Ghent promoters. The evaluation is performed in vivo using imaging techniques (MicroSPECT and BLI) in collaboration with the VUB team.
-
- Journal Article
- A1
- open access
Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models
-
- Journal Article
- A1
- open access
Xenogeneic equine stem cells activate anti-tumor adaptive immunity in a 4T1-based intraductal mouse model for triple-negative breast cancer : proof-of-principle
-
- Journal Article
- A1
- open access
One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer